ersentilidumersentilideersentilideersentilidaexamorelinumexamorelinexamorélineexamorelinafampridinumfampridinefampridinefampridinafaropenemumfaropenemfaropénemfaropenemfenleutonumfenleutonfenleutonfenleuton4'-[(2S)-2-hydroxy-3-[[2-(p-imidazol-1-ylphenoxy)ethyl]amino]propoxy]=methanesulfonanilideN-[4-[[(S)-2-hydroxy-3-[[2-[4-(1H-imidazol-1-yl)phénoxy]éthyl]amino]propyl]=oxy]phényl]méthanesulfonamide4'-[(2S)-2-hidroxi-3-[[2-(p-imidazol-1-ilfenoxi)etil]amino]propoxi]=metansulfonanilidaC 21H 26N 4O 5SL-histidyl-2-methyl-D-tryptophyl-L-alanyl-L-trypfophyl-D-phenylalanyl-L-lysinamideL-histidyl-(2-méthyl-D-tryptophyl)-L-alanyl-L-tryptophyl-D-phénylalanyl-L-lysinamideL-histidil-2-metil-D-triptofil-L-alanil-L-triptofil-D-fenilalanil-L-lisinamidaC 47 H 58 N 12 O 64-aminopyridinepyridin-4-ylamine4-aminopiridinaC 5 H 6 N 2(+)-(5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-tetrahydro-2-furyl]-4-thia-1 -azabicyclo[3.2.0]hept-2-ene-2-carboxylic acidacide (+)-(5a6S)-6-[(1R)-1-hydroxyéthyl]-7-oxo-3-[(2R)-tétrahydrofuran-2-yl¡-4-thia-1-azabicyclo[3.2.0]hepf-2-ène-2-carboxyliqueácido (+)-(5R,6S)-6-[(1R)-1 -hidroxietil]-7-oxo-3-[(2R)-tetrahidro-2-furil]-4-tia-1-azabiciclo[3.2.0]hept-2-en-2-carboxílicoC 12 H 15 NO 5 S(±)-1-[3-[m-(p-fluorophenoxy)phenyl]-1-methyl-2-propynyl]-1-hydroxyurea(±)-1 -[(1RS)-3-[3-(4-fluorophénoxy)phényl]-1 -méthylprop-2-ynyl]-1 -hydroxyurée(±)-1-[3-[m-(p-fluorofenoxi)fenil]-1-metil-2-propinil]-1-hidroxiureaC 17H 15FN 2O 3fodipirumfodipirfodipirfodipirN,N-ethylenebis[N-[[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridyl]=methyl]glycine] 5,5'-bis(dihydrogenphosphate)N,N'-éfhane-1,2-diylbis[N-[[3-hydroxy-2-méthyl-5-[(phosphonooxy)méthyl]=pyridin-4-yl]méthyl]glycine]N,N'-etilenbis[N-[[3-hidroxi-5-(hidroximetil)-2-metil-4-piridil]metil]glicina]5,5'-bis(dihidrógenofosfato)C 22H 32N 4O 14P 2
follitropinum alfafollitropin alfafollitropine alfafolitropína alfafollicle-stimulating hormone, glycoform αα-subunit:chorionic gonadotropin (human α-subunit protein moiety reduced)β-subunit:follicle-stimulating hormone (human clone λ 15B β-subunit protein moietyreduced)hormone folliculo-stimulante, forme glycosylée αSous-unité a :gonadotropins chorionique (partie protéique réduite de la sous-unité αhumaine)Sous-unité β :hormone folliculo-stimulante (partie protéique réduite de la sous-unité β duclone humain λ 15B)hormona estimulante del folículo, glicoforma αsubunidad α :gonadotropina coriónica (fracción proteica reducida de la subunidad αhumana)subunidad β:hormona estimulante del folículo (fracción proteica reducida de la subunidadβ del clon humano humane λ 15B)α :C437H682N122O134S13β :C538H833N145O171S13fradafibanumfradafibanfradafibanfradafiban(3S,5S)-5-[[(4'-amídino-4-biphenylyl)oxy]methyl]-2-oxo-3-pyrrolidineaceticacidacide 2-[(3S,5S)-5-[[(4'-amidinobiphényl-4-yl)oxy]méthyl]-2-oxopyrrolidin-3-yl]acétiqueacido (3S,5S)-5-[[(4'-amidino-4-bifenilil)oxi]metil]-2-oxo-3-pirrolidínacéticoC20H21N3O4fuladectinumfuladectin a mixture of components A 4 and A 3 ,component A 4 (major component):4'-[2-[[(2ae,4e,5'S,6S,6'R,7O,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-ethyl-3', 4', 5', 6, 6',7, 10, 11, 14, 15, 17a,20,20a,20b-tetradecahydro-20,20bdihydroxy-5',6,8,19-tetramethyl-17-oxospiro[11,15-methano-2H,13H, 17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2'-[2H]pyran]-7-yl]oxy]ethyl]-N-methylmethanesulfonanilidecomponent A 3 (minor component):4'-[2-[[(2aE,4E,5'S,6S,6'R,7R,8E,11R,13R,15S,17aR,20R,20aR,20bS)-3',4',5',6,6',7,10,11,14,15,17a,20,20a,20b-tetradecahydro-20,20b-dihydroxy-5',6,6',8,19-pentamethyl-17-oxosp¡ro[11,15-methano-2H, 13H, 17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2'-[2H]pyran]-7-yl]oxy]ethyl]-Wmethylmethanesulfonanilide
- Page 1 and 2: WHODRUGINFORMATIONV O L U M E 9 •
- Page 3: WHO Drug InformationContentsGeneral
- Page 7 and 8: 2. Geiling, E., Cannon, P. Patholog
- Page 9 and 10: Magnesium sulfate held no statistic
- Page 11 and 12: • In control programmes involving
- Page 13 and 14: 31. Addiss, D., Eberhard, M., Lammi
- Page 15 and 16: esponse to treatment need more syst
- Page 17 and 18: 2. Nichol, K., Margolis, K., Wuoren
- Page 19 and 20: 9. Thumham, D. Vitamin A deficiency
- Page 21 and 22: Instilled prophylactically before o
- Page 23 and 24: months of administration, ivermecti
- Page 25 and 26: General Information"Natural" medici
- Page 27 and 28: 12. Moertel, C, Fleming, T., Rubin,
- Page 29 and 30: In the United Kingdom, a working gr
- Page 31 and 32: healers require education to recogn
- Page 33 and 34: 4. Federal regulations that are dev
- Page 35 and 36: Several benefits are identified tha
- Page 37 and 38: To detect vancomycin-resistant ente
- Page 39 and 40: particularly long half-life, this p
- Page 41 and 42: for less severe forms of acne, hirs
- Page 43 and 44: International Nonproprietary Names
- Page 45 and 46: adefovirumadefoviradéfoviradefovir
- Page 47 and 48: cefoselisumcefoseliscéfoséliscefo
- Page 49: efegatranumefegatranéfégatranefeg
- Page 53 and 54: idramantonumidramantoneidramantonei
- Page 55 and 56: lanprostonumlanprostonlanprostonela
- Page 57 and 58: mapinastinummapinastinemapinastinem
- Page 59 and 60: napsagatranumnapsagatrannapsagatran
- Page 61 and 62: orientiparcina mezcla de orienticin
- Page 63 and 64: prulifloxacinumprulifloxacinprulifl
- Page 65 and 66: tagorizinumtagorizinetagorizinetago
- Page 67 and 68: zifrosilonumzifrosilonezifrosilonez
- Page 69: SELECTED WHO PUBLICATIONSOF RELATED